Mesoblast Ltd (MESO)

NASDAQ
Currency in USD
18.540
+0.300(+1.64%)
Closed
After Hours
18.900+0.360(+1.942%)
MESO Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
Earnings results expected in 7 days
Fair Value
Day's Range
18.14018.720
52 wk Range
1.83022.000
Key Statistics
Edit
Prev. Close
18.24
Open
18.37
Day's Range
18.14-18.72
52 wk Range
1.83-22
Volume
185.75K
Average Vol. (3m)
487.48K
1-Year Change
863.7%
Book Value / Share
0.42
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MESO Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
27.000
Upside
+45.63%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins
Show more

Mesoblast Ltd Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Compare MESO to Peers and Sector

Metrics to compare
MESO
Peers
Sector
Relationship
P/E Ratio
−26.9x−1.8x−0.6x
PEG Ratio
−1.77−0.040.00
Price / Book
4.9x1.3x2.6x
Price / LTM Sales
401.6x101.6x3.1x
Upside (Analyst Target)
48.0%282.6%52.8%
Fair Value Upside
Unlock−10.0%8.4%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 27.000
(+45.63% Upside)

Earnings

Latest Release
Nov 20, 2024
EPS / Forecast
-0.14 / -0.099
Revenue / Forecast
1.49M / 9.25M
EPS Revisions
Last 90 days

People Also Watch

10.6200
PDYN
+3.51%
2.92
RZLV
-4.26%
11.750
RGTI
+6.62%
1.960
QSI
+2.08%
6.450
AUR
-7.86%

FAQ

What Is the Mesoblast (MESO) Stock Price Today?

The Mesoblast stock price today is 18.54

What Stock Exchange Does Mesoblast Trade On?

Mesoblast is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Mesoblast?

The stock symbol for Mesoblast is "MESO."

What Is the Mesoblast Market Cap?

As of today, Mesoblast market cap is 2.34B.

What is Mesoblast Earnings Per Share?

The Mesoblast EPS is -0.089.

What Is the Next Mesoblast Earnings Date?

Mesoblast will release its next earnings report on Feb 20, 2025.

From a Technical Analysis Perspective, Is MESO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.